sNDA Puts Velcade Ahead of Revlimid in Race To First-Line Multiple Myeloma Market
This article was originally published in The Pink Sheet Daily
Executive Summary
If FDA grants priority review, a decision for Millenium’s product could come as early as mid-2008.
You may also be interested in...
Celgene Partners With Acceleron On Novel Bone Forming Compound
$997 million deal will includes ACE-011 for cancer-related bone loss and other discovery compounds.
Celgene Partners With Acceleron On Novel Bone Forming Compound
$997 million deal will includes ACE-011 for cancer-related bone loss and other discovery compounds.
Millennium Pushing Ahead With Velcade In Non-Hodgkins Lymphoma
NHL population represents a greater opportunity than all multiple myeloma settings combined, CEO Dunsire says during business update.